- Home
- LODE vs PLX Comparison
LODE vs PLX Comparison
Compare LODE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LODE | PLX |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 204.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | LODE | PLX |
|---|---|---|
| Price | $3.29 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 831.1K | 529.2K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $2,778,445.00 | ★ $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | $1,798.62 | $16.65 |
| P/E Ratio | ★ N/A | $25.92 |
| Revenue Growth | ★ 48.99 | 35.41 |
| 52 Week Low | $1.67 | $1.32 |
| 52 Week High | $10.10 | $3.10 |
Technical Indicators
Market Signals| Indicator | LODE | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 41.00 |
| Support Level | $3.13 | $1.68 |
| Resistance Level | $3.75 | $1.86 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 28.23 | 52.38 |
Price Performance
Historical ComparisonAbout LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.